NorthStar Medical Technologies to Present at Upcoming Biotech Showcase 2020

BELOIT, Wis. – December 16, 2019 – NorthStar Medical Technologies, LLC, a global innovator in the production and distribution of radioisotopes used for medical imaging, today announced that it will participate in the upcoming Biotech Showcase™ 2020, being held January 13 ‒ 15, 2020, in San Francisco, Ca. Biotech Showcase is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for executives and investors that fosters investment and partnership opportunities.

Stephen Merrick, President and Chief Executive Officer of NorthStar Medical Technologies, will present and provide an update on NorthStar and its progress in advancing U.S. radioisotope production. Mr. Merrick and Paul Estrem, Senior Vice President and Chief Financial Officer, will conduct meetings with institutional investors in conjunction with the event. Meetings can be arranged through the Biotech Showcase 2020 website or by contacting NorthStar Investor Relations. The NorthStar presentation is scheduled for Monday, January 13, 2020, at 4:00 p.m. Pacific Time, in Franciscan Room C (Ballroom Level) at the Hilton San Francisco Union Square Hotel.

About Biotech Showcase
Biotech Showcase is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place. Investors and biopharmaceutical executives from around the world gather in San Francisco during this bellwether week which sets the tone for the coming year. Now in its 12th year, this well-established, highly respected conference features multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings. Biotech Showcase is produced by Demy-Colton and EBD Group. Both organizations have a long history of producing high-quality programs that support the biotechnology and broader life sciences industry.

About NorthStar Medical Technologies, LLC (NorthStar)
NorthStar Medical Radioisotopes is a global innovator in the production and distribution of radioisotopes used for medical imaging. Founded in 2006 and based in Beloit, Wis., NorthStar Medical Technologies is the parent organization of several wholly-owned subsidiaries, including NorthStar Medical Radioisotopes, LLC. NorthStar Medical Radioisotopes is a nuclear medicine technology company committed to providing the United States with reliable and environmentally friendly radioisotope supply solutions to meet the needs of patients and to advance clinical research. The Company’s first product is the RadioGenix® System, an innovative and flexible platform technology initially approved by the U.S. Food and Drug Administration in February 2018 for the processing of non-uranium/non-highly enriched uranium based molybdenum-99 (Mo-99), the parent isotope of technetium-99m (Tc-99m), which is currently the most widely used diagnostic radioisotope for medical purposes. NorthStar’s proprietary and patented technologies include non-uranium based molybdenum-99 domestic production methods, patented separation chemistry systems, patented sterilization systems and a technology platform that potentially allows expanded product offerings to provide solutions in both the diagnostic and therapeutic markets. For more information, visit:

Corporate Contact:
For NorthStar Medical Technologies, LLC
Lisa Holst
Vice President Sales and Marketing
[email protected]

Investor Relations:
For NorthStar Medical Technologies, LLC
Paul Estrem, CPA
Senior Vice President and Chief Financial Officer
[email protected]

Media Contact:
For NorthStar Medical Technologies, LLC
Priscilla Harlan
[email protected]